



Universiteit
Leiden
The Netherlands

Haemodynamics in children with a Fontan circulation: effects of afterload reduction

Harteveld, L.M.

Citation

Harteveld, L. M. (2023, October 12). *Haemodynamics in children with a Fontan circulation: effects of afterload reduction*. Retrieved from <https://hdl.handle.net/1887/3643760>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3643760>

Note: To cite this publication please use the final published version (if applicable).



Chapter

8



Treatment and outcome of plastic bronchitis in single ventricle patients: a systematic review

Interactive Cardiovascular and Thoracic Surgery. 2020 Jun 1;30(6):846-853

Lisette M. Hartevel
Nico A. Blom
Mark G. Hazekamp
Arend D.J. Ten Harkel



Abstract

Plastic bronchitis (PB) is a life-threatening complication in single ventricle (SV) patients of which the exact pathophysiology, outcome and optimal treatment are still unclear. This study aims to systematically review the literature to give insight into the characteristics, outcome and management options of SV patients with PB. A systematic review was conducted, using the electronic database PubMed to find records published up to August 2018, describing SV patients and PB in which characteristics, treatment and/or outcome were adequately described per case. A total of 577 records were screened of which 73 had sufficient data describing 133 SV cases with PB. Most cases had completed a Fontan palliation ($n = 126$) with a median interval between Fontan completion and diagnosis of PB of 18.4 months (Q1-Q3 5.0-36.3). Overall mortality was 15.2% and was associated with diagnosis of PB within 12 months after Fontan palliation (5-year survival of 56.1% ≤ 12 months vs 94.8% > 12 months, $P = 0.002$) and a higher age at Fontan completion (47.4 months for non-survivors vs 36.0 months for survivors, $P = 0.015$). Most patients received a combination therapy from 3 different treatment strategies, i.e. therapy for relief of airway obstruction, anti-inflammatory treatment and treatment to improve haemodynamics of the Fontan physiology (55.1%). In conclusion, SV patients who are diagnosed with PB within 12 months after Fontan palliation have a higher risk of mortality. Moreover, most cases received a combination therapy consisting of all 3 treatment strategies.

Introduction

Plastic bronchitis (PB) is a rare and life-threatening condition characterized by the formation of mucofibrinous casts within the tracheobronchial tree leading to airway obstruction and potentially asphyxia. PB has been described as a complication of respiratory disorders, lymphatic abnormalities and infections but particularly occurs in patients with a single ventricle (SV) after Fontan palliation (1) in which the prevalence has been estimated to be 2-8% (2-4). However, literature describing PB in Fontan patients usually consists of case reports and case series. As a result, knowledge of patient characteristics, survival and possible factors associated with disease outcome is limited. PB has a multifactorial pathogenesis, in which genetic and environmental factors, inflammation and the Fontan physiology itself, with elevated systemic venous pressure, seem to play an important role (5). There is a wide range of therapeutic strategies of which no specific regimen has proven to be consistently effective. A better understanding of SV patients with PB and all therapeutic options is important to recognize patients at risk and improve treatment strategies.

This study aims to systematically review the literature to give insight into the characteristics and outcome of patients with PB after SV palliation, as well as the therapeutic options to treat PB. Furthermore, a case report is presented to illustrate treatment options.

Case report

A boy born with tricuspid atresia and ventricular septal defect received an atrioseptectomy, banding of the main pulmonary artery and bidirectional Glenn anastomosis at the age of 3 months without complication. At the age of 4 years, there were low pulmonary artery pressures post-Glenn (11-12 mmHg) and good left ventricular function. Therefore, the patient received an extracardiac total cavopulmonary connection with a fenestration and division of the main pulmonary artery. The age at which the Fontan operation was performed is in concordance with our institutional standards (6). At the age of 6, 9 months after fenestration closure with an Amplatzer septal device, the patient developed PB with episodes of respiratory distress and daily coughing up large casts.

Diagnostic evaluation showed normal cardiac function, an unobstructed cavopulmonary circuit with a mean pressure of 15-17 mmHg, absence of aortopulmonary collaterals and a mild asymptomatic sinus node dysfunction with

a nodal escape rhythm of 75 beats per minute. There appeared to be a relation between the onset of PB and the fenestration closure. Because of recurrent life-threatening episodes, despite therapy with salbutamol and hypertonic saline, there was opted for an aggressive approach by lowering the pulmonary artery pressure by a Fontan takedown in combination with atrial pacing. The Fontan takedown consisted of removal of the entire extracardiac conduit, reconnection of the inferior caval vein to the right atrium and placement of a central aortopulmonary shunt to improve saturation. Furthermore, for atrial pacing a pacemaker system (*Atrial-pacing Atrial-sensing Inhibited-response Rate-adaptive (AAIR)*) was implanted.

Postoperative treatment consisted of azithromycin, a medium-chain triglyceride diet and nebulization with mucolytics, bronchodilators and beclomethasone. Postoperatively, bronchoscopy was necessary to remove a large cast (Figure. 1) and sildenafil, bosentan and nebulization with alteplase were added. Eventually, symptoms of PB ceased and all medications were successfully weaned without recurrence. Due to severe cyanosis and reduced exercise intolerance, it was decided to redo a total cavopulmonary connection with fenestration 4.5 years after Fontan takedown. Haemodynamic assessment before the operation showed low pulmonary artery pressures (6-7 mmHg). Postoperatively, the patient's physical condition improved substantially and currently, >1.5 years post-redo-Fontan completion, he had no recurrence and only receives phenprocoumon and azithromycin.



Figure 1. Expectorated bronchial cast

Materials and Methods

A systematic review of published studies describing SV patients with PB was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement protocol (7). The PubMed database was used to search relevant records published up to August 2018, date of search 13 August 2018 (Figure 2). The following search terms were used: plastic bronchitis OR bronchial cast OR bronchial casts. The search was performed by the primary author (L.M.H.).

Titles and abstracts were screened and selected based on the following predefined criteria: the entire or partial study population consisting of SV patients who were diagnosed or treated for PB and characteristics, treatment and/or outcome being well described per case. All full-text records were studied, and non-English records were excluded. The case presented by our own centre was also included.

The following data were extracted: publication year, number of SV cases with PB and per case gender, type SV, type palliation, age at PB diagnosis, age at Glenn or Fontan

operation, follow-up time after diagnosis, history of chylothorax or protein-losing enteropathy (PLE), treatment received and outcome after treatment. Therapeutic options were divided into relief of airway obstruction, anti-inflammatory treatment and treatment improving haemodynamics of the Fontan physiology. Furthermore, characteristics between patients who survived or died were compared as well as survival between patients diagnosed within or after 12 months after Fontan completion.

Statistical analyses

Categorical data were extracted per case based on the presence or absence of a certain variable. Regarding the continuous data, all available data per individual case were directly extrapolated from the article. Although most articles provided data per individual case, a few articles only provided data on a group level. For those articles we had to make assumptions and therefore we used the available median of the entire group that was described in the article. This was necessary for 9 cases and only for the follow-up time since diagnosis of PB. Moreover, for 1 article we had to use 2 medians' to extract the necessary data for 2 cases (8). Data are presented as numbers with percentages for categorical data and median with first to third quartiles (Q1-Q3) for continuous data. To determine risk factors for negative outcome, continuous data were analysed using the Mann-Whitney *U*-test and categorical data using the Fisher's exact test. Kaplan-Meier curves were conducted to present overall survival and to compare the difference in survival between patients who were diagnosed with PB within or after 12 months after Fontan completion using the log-rank test.

SPSS (version 23) software was used. A *P*-value of 0.05 or less was considered statistically significant.

Results

Of the 577 records found in PubMed, 88 contained titles and abstracts that met the inclusion criteria. After studying the records in full text, 73 describing 133 PB cases were included in the review (Figure. 2). Fifty-three records consisted of a single case report, 18 records consisted of small case series and 2 records consisted of larger case series (see Supplementary Material, *Table S1*).




Figure 2. Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow diagram of search results.

Patients characteristics are described in Table 1. Most cases were diagnosed with PB after Fontan palliation ($n = 126$) with a median age at the diagnosis of 60.0 months and the median time from Fontan to diagnosis of 18.4 months. Seven patients had a bidirectional Glenn anastomosis at the time of diagnosis. The median follow-up time after diagnoses was 18.0 months. After diagnosis, 10 cases needed extracorporeal membrane oxygenation support of which 2 eventually died. Overall mortality was 15.2% with a 5-year survival of 77.4% (Figure. 3). Furthermore, mortality seemed to have decreased over time as the mortality rate in articles published before 2012 was found to be 24.4% compared to 10.5% in articles published between 2012 and 2018. The median time to death after diagnosis was 3.5 months. Resolution of PB occurred in 51.5%, with 26.8% still experiencing symptoms at the end of follow-up.

Table 1. Characteristics and outcome of cases

Variables	
Sex (<i>n</i> = 104)	
Male	66 (63.5)
Female	38 (36.5)
Type single ventricle (<i>n</i> = 104)	
Single left ventricle	51 (49.0)
Single right ventricle	53 (51.0)
Type palliation (<i>n</i> = 133)	
Fontan	126 (94.7)
Glenn	6 (4.5)
Hemi-Fontan	1 (0.8)
Age at diagnosis of PB (<i>n</i> = 112, months)	60.0 (41-83.8)
Age at Glenn operation (<i>n</i> = 5, months)	6.0 (5.1-72.5)
Interval between Glenn operation and PB (<i>n</i> = 5, months)	12.0 (9.5-64.1)
Age at Fontan operation (<i>n</i> = 98, months)	36.6 (25.8-51.5)
Interval between Fontan operation and PB (<i>n</i> = 110, months)	18.4 (5-36.3)
Follow-up since diagnosis of PB (<i>n</i> = 126, months)	18.0 (6.8-37.1)
History of chylothorax	35 (26.3)
History of or occurrence of PLE alongside PB	6 (4.5)
Patients who received ECMO	10 (7.5)
Outcome at follow-up (<i>n</i> = 132)	
<i>Death</i>	20 (15.2)
<i>Alive</i>	112 (84.8)
Symptom free of PB at follow-up	68 (51.5)
Still symptoms of PB at follow-up	30 (22.7)
Unknown	14 (10.6)

All values are expressed as *n* (%) or median (Q1-Q3).

ECMO: Extracorporeal membrane oxygenation; PB: Plastic Bronchitis; PLE: Protein losing enteropathy.




Figure 3. Kaplan-Meier curve of overall survival of Fontan patients after Dx with plastic bronchitis. Dx: diagnosis; PB: plastic bronchitis.

An older age at the time of Fontan operation (Table 2; 47.4 months for non-survivors vs 36.0 months for survivors) and the diagnosis of PB within 12 months after Fontan completion (Figure 4; 5-year survival of 56.1% with diagnosis ≤ 12 months vs 94.8% >12 months) were associated with an increased risk of mortality.

Table 2. Comparison of the characteristics between patients who survived or died after diagnosis of PB

Characteristics	Alive (n = 113)	Death (n = 20)	P-value
Gender (n = 104)			1.000
Female	32 (36.4)	6 (37.4)	
Male	56 (63.6)	10 (62.5)	
Type single ventricle (n = 104)			1.000
Single left ventricle	45 (49.5)	6 (50.0)	
Single right ventricle	46 (50.5)	6 (50.0)	
Age at diagnosis of PB (n = 111, months)	60.0 (39.6-84.0)	55.0 (49.7-90.8)	0.854
Age at Fontan operation (n = 97, months)	36.0 (25.0-48.0)	47.4 (42.9-75.0)	0.015
Interval between Fontan operation and PB (n = 109, months)	23.9 (6.0-43.2)	6.0 (3.0-12.8)	0.052
History of chylothorax	25 (22.1)	9 (45.0)	0.387
History of/or occurrence of PLE alongside PB	5 (4.4)	1 (5.0)	1.000
Patients who received ECMO	7 (6.2)	2 (10.0)	0.279

All values are expressed as n (%) or median (Q1-Q3).

ECMO: Extracorporeal membrane oxygenation; PB: Plastic Bronchitis; PLE: Protein-losing enteropathy.




Figure 4. Kaplan–Meier curve of survival of Fontan patients after Dx with plastic bronchitis based on period of Dx after Fontan palliation, Dx within 12 months (light blue dotted line) and after 12 months (dark blue solid line) after Fontan palliation. The P-value of the log-rank test between groups is indicated in the graph. Dx: diagnosis; PB: plastic bronchitis.

Treatments were divided into 3 different treatment strategies (Table 3): (i) therapy for relief of airway obstruction, (ii) anti-inflammatory treatment and (iii) treatment improving the haemodynamics of the Fontan physiology. Most patients received a combination therapy from all 3 different treatment strategies (55.1%). In 6 patients treatment was not defined. Relief of airway obstruction was the most frequently reported strategy (91.3%), especially during the acute phase of PB. More than 50% of the patients received a combination of different aerosolized drugs for cast relief. Anti-inflammatory therapy was the least frequently reported (65.4%). Therapy improving haemodynamics was variable and consisted of optimizing the Fontan circulation or cardiac function (61.4%), antiarrhythmic therapy (8.7%), inhibition of lymph leakage/production (33.1%), decompression of the Fontan circulation (23.6%) and heart transplantation (9.4%).

Table 3. Description of therapeutic options applied for treatment of PB

	Total (n =127)
Relief of airway obstruction	116 (91.3)
Bronchoscopic cast extraction	62 (48.8)
Chest physiotherapy	31 (24.4)
Mechanical ventilation therapy	6 (4.7)
<i>Fibrinolytics (total)</i>	75 (59.1)
Tissue plasminogen activator/ Urokinase	70 (55.1)
Nebulized heparin	10 (7.9)
Mucolytics (total)	73 (57.5)
Bronchodilators	76 (59.8)
Anti-inflammatory	83 (65.4)
Corticosteroids	74 (58.3)
Antibiotics	37 (29.1)
Haemodynamics (CO/CVP/Lymph)	102 (80.3)
<i>Optimizing Fontan circulation or cardiac function</i>	78 (61.4)
Fontan conversion	1 (0.8)
Fontan revision	2 (1.6)
Surgical or interventional relief of Fontan circuit obstruction	25 (19.7)
Valve replacement	2 (1.6)
Ligation/embolization of aortopulmonary collaterals	17 (13.4)
Pulmonary vasodilators (total)	57 (44.9)
Bosentan	18 (14.2)
Sildenafil	54 (42.5)
Systemic prostacyclin	2 (1.6)
Heart failure therapy/medication	22 (17.3)
<i>Anti-arrhythmic therapy</i>	11 (8.7)
Pacemaker therapy	9 (7.1)
Ablation	1 (0.8)
Antiarrhythmic agents	1 (0.8)
<i>Inhibition of lymph leakage/production</i>	42 (33.1)
Low fat diet	13 (10.2)
Octreotide	1 (0.8)
Ligation/embolization of thoracic duct or lymphatic vessels	33 (26.0)
<i>Decompression of Fontan circulation</i>	30 (23.6)
Creation, dilation or stenting of fenestration	24 (18.9)
Takedown of Fontan circulation	6 (4.7)
<i>Heart transplantation</i>	12 (9.4)

All n (%) values represent number of cases in which the value was described. CO: cardiac output; CVP: central venous pressure; PB: Plastic bronchitis.

Discussion

PB is a rare complication in SV patients. Through collecting all available SV cases, we were able to describe characteristics, survival and therapy of 133 cases. Major findings include an overall mortality of 15.2%, diagnosis within 12 months after Fontan palliation and a higher age at Fontan operation, both of which are associated with increased risk of mortality. Moreover, the majority of cases received a combination therapy consisting of all 3 treatment strategies.

Mortality in this review was considerably lower compared to previous reports. A case-control study reported an overall mortality of 32.0% in Fontan patients diagnosed before 2012 (9). If we compare mortality within our review, mortality is higher in cases published before 2012 which may imply improving survival. Moreover, recent studies of PLE in Fontan patients also reported improved survival (10). Nevertheless, these higher survivals could be caused by improvement in the survival of all Fontan patients. Furthermore, mortality of PLE is higher (26.0-40.0%) (6, 10) and resolution after treatment much lower (31%)(6) when compared to PB (51.5%). Although both diseases share a similar pathological basis, PB is an acute disease that typically appears shortly after Fontan operation while PLE typically appears in a more chronic fashion several years after operation (6, 10).

One study reported that an earlier onset of PB after the Fontan palliation was associated with a higher risk of mortality (9), a risk factor we also found. However, early onset of PB may be a manifestation of a poor Fontan circulation and may therefore be correlated with an increased risk of death. Furthermore, we found an older age at Fontan operation as an additional risk factor. Whether this finding has been influenced by other factors could not be determined. For example, patients may have been operated late because they were suboptimal Fontan candidates. Nevertheless, it seems to be in line with most series that older age at Fontan operation is an independent risk factor for poor outcome (11-13). Other variables of interest for mortality, such as elevated Fontan pressures and ventricular function, or possible risk factors for the development of PB, could not be analysed in our study. In our case, the onset of PB seemed to be related to an elevated Fontan pressure after fenestration closure.

Treatment

We divided treatments into 3 therapeutic strategies including relief of airway obstruction, anti-inflammatory treatment and treatment improving haemodynamics of the Fontan physiology. Most patients described in the literature, including our

case, received a combination of all treatment strategies, which eventually led to the successful management of PB in the majority of cases. Therefore, based on all cases included in this systematic review, we developed a treatment algorithm in which treatment after the acute phase consists of a combination of all 3 different treatment strategies (Figure 5).




Figure 5. Treatment algorithm for Fontan patients diagnosed with plastic bronchitis. tPA: tissue plasminogen activator.

Relief of airway obstruction

In emergency cases, immediate bronchoscopy should be considered. However, complete lavage is not always possible as casts are often fragile. Alternatively, mechanical ventilation with positive-negative pressure (14-17) or high frequency jet ventilation (18) can be used for cast relief. However, a need for high airway pressure and repeated bronchoscopies should be avoided as both will decrease passive blood flow through the pulmonary system, negatively affecting the cardiac output of Fontan patients (19). With the absence of acute respiratory failure, treatment with chest physiotherapy, bronchodilators, mucolytics and fibrinolytics can be initiated to enhance cast expectoration or to induce the lysis of casts. Inhalation of plasminogen activator, a fibrinolytic, has proven to be an effective and safe treatment for cast

reduction (20-23), acute exacerbations (24) and chronic therapy in preventing cast formation (21, 25). Although all these therapies may be effective for cast relief, they are not able to prevent recurrence.

Anti-inflammatory treatment

Because some casts consist of inflammatory cells (21, 26) and since there is a relation between PB and acute respiratory infections (2), anti-inflammatory treatment has been frequently used. This most often consists of inhaled corticosteroids and antibiotic treatment. Yet, evidence of effectiveness of steroids is limited. However, a case with acellular casts resolution appeared after the introduction of corticosteroids (27) and another case remained cast free while chronically on steroid treatment (26). Inhaled steroids may be effective as it is believed that altered Fontan haemodynamics cause mucosal injury inducing mild airway inflammation. Furthermore, as cast recurrence has been associated with respiratory infections (21), prophylactic antibiotic treatment may be a useful adjunct therapy for recurrence prevention, as shown in our case and another case report (28).

Therapy improving the Fontan circulation

The Fontan physiology itself also contributes to the development of PB. A lower cardiac output, elevated systemic venous pressure and abnormal lymphatic flow may contribute (5). Therefore, a thorough diagnostic evaluation of the Fontan circulation is essential to determine a therapeutic strategy. Nevertheless, the onset of PB can occur in Fontan patients with relative normal Fontan pressures with preserved cardiac function without residual lesions (21, 26).

Relief or repair of residual lesions and obstructions have to be considered. Resolution of PB has been reported after successful interventions for ventricular, arterial and venous obstruction atrioventricular valve regurgitation and aorta-pulmonary collaterals (21). Although these results are promising, not every intervention in each individual will lead to successful treatment (5, 29, 30). In addition, medical therapies may also improve haemodynamics and optimize the circulation. Pulmonary vasodilators, sildenafil and bosentan in particular have shown to be an effective and safe treatment that can be administered chronically (21, 26, 31-33).

Improvement in cardiac output can be obtained by antiarrhythmic therapy. Atrial pacing may restore chronotropic incompetence and atrioventricular synchrony but has only led to the resolution of PB in some cases (1, 34, 35), while others report less favourable results (5, 23, 25, 36, 37).

Inhibition of lymph production or leakage could be an effective therapy, especially in those who previously had a chylothorax or currently have chylous casts. A low-fat or medium-chain triglyceride diet has proven to be successful (37, 38). However, recurrence can occur when the diet is stopped (37). Furthermore, interruption of lymphatic flow through embolization or ligation has shown to improve symptoms and even temporarily resolution (26). However, not all patients have abnormal lymphatic flow (26). Therefore, lymphatic imaging should ideally be part of the diagnostic evaluation.

If the Fontan circulation cannot be further optimized, then decompression should be considered. A Fontan takedown to a Glenn physiology as well as fenestration of the Fontan pathway can result in reduced venous pressures and improved cardiac output. However, both therapies have shown various effects, with results ranging from no effect (39-41) to the improvement of symptoms (21, 26, 31, 39, 42) or even complete resolution (21, 36, 43-46). Although catheter-created fenestration is the least invasive method, the chance of spontaneous closure is high (36). Furthermore, when surgery is considered, a takedown will have the largest effect on lowering venous pressures and improving cardiac output but also will result in significant cyanosis, which can be a complicating factor if PB persists. In our case, the severe PB, which developed after fenestration closure, resolved after temporary Fontan takedown and appeared to be a successful therapy by drastically decreasing the pulmonary circulation. After the resolution of casts and a long recovery period, re-Fontan procedure with a relatively large fenestration was feasible without PB recurrence.

Besides improving the hemodynamic of the Fontan circulation itself, a heart transplantation could be considered in some cases. Although Fontan patients with PB have a high mortality peri-transplantation (47, 48), long-term mortality is comparable to the general paediatric heart transplant population (47). As residual casts may be present, airway clearance during and early after transplantation is necessary to reduce postoperative morbidity (49, 50). Cardiac transplantation could be very successful for treating PB, as in a large group of Fontan patients with PLE resolution occurred in almost all cases after heart transplantation (51).

Limitations

This review includes only patients already diagnosed with PB, and therefore we could not identify risk factors for PB itself. Furthermore, missing data and reporting bias were present due to the inclusion of case reports. For example, we were not

able to report the type of Fontan operation performed. Potential risk factors such as haemodynamic measurements of cardiac catheterization could not be studied, as they were only infrequently reported in the cases. Due to the possible presence of publication bias, the study population may also not be representative of the total population of Fontan patients with PB. However, missing data and reporting bias may have biased results in both directions. Finally, due to the many therapy types, it was only possible to provide an overview instead of an analysis of different therapeutic strategies.

Conclusion

Most SV patients with PB are diagnosed early after the Fontan operation with approximately one-sixth dying shortly after diagnosis. Furthermore, diagnosis of PB within 12 months after Fontan palliation and a higher age at Fontan operation are associated with an increased risk of mortality. Whether these findings are independent predictors for mortality could not be investigated. Although treatments varied enormously and none has proven to be consistently effective, this study together with our own experience suggests that therapy of PB consisting of relief of airway obstruction, anti-inflammatory treatment and treatment improving haemodynamics of the Fontan physiology can be an effective strategy to cure PB. In addition, a temporary Fontan takedown could be a life-saving therapy. During this period, PB can resolve, pulmonary circulation can recover and the Fontan circulation could be restored successfully at a later time. Nevertheless, large multicentre cohort studies are warranted to unravel the exact pathophysiology to determine which patients are at risk for developing PB and which therapeutic strategy is most effective.

References

1. Brogan TV, Finn LS, Pyskaty DJ, Jr., Redding GJ, Ricker D, Inglis A, et al. Plastic bronchitis in children: a case series and review of the medical literature. *Paediatric pulmonology*. 2002;34(6):482-7.
2. Schumacher KR, Stringer KA, Donohue JE, Yu S, Shaver A, Caruthers RL, et al. Fontan-associated protein-losing enteropathy and plastic bronchitis. *The Journal of pediatrics*. 2015;166(4):970-7.
3. Caruthers RL, Kempa M, Loo A, Gulbransen E, Kelly E, Erickson SR, et al. Demographic characteristics and estimated prevalence of Fontan-associated plastic bronchitis. *Paediatric cardiology*. 2013;34(2):256-61.
4. Allen KY, Downing TE, Glatz AC, Rogers LS, Ravishankar C, Rychik J, et al. Effect of Fontan-Associated Morbidities on Survival With Intact Fontan Circulation. *The American journal of cardiology*. 2017;119(11):1866-71.
5. Larue M, Gossett JG, Stewart RD, Backer CL, Mavroudis C, Jacobs ML. Plastic bronchitis in patients with fontan physiology: review of the literature and preliminary experience with fontan conversion and cardiac transplantation. *World journal for paediatric & congenital heart surgery*. 2012;3(3):364-72.
6. Rijnberg FM, Blom NA, Sojak V, Bruggemans EF, Kuipers IM, Rammeloo LAJ, et al. A 45-year experience with the Fontan procedure: tachyarrhythmia, an important sign for adverse outcome. *Interactive cardiovascular and thoracic surgery*. 2019.
7. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews*. 2015;4:1.
8. Unseld B, Stiller B, Borth-Bruhns T, du Bois F, Kroll J, Grohmann J, et al. An Early Glenn Operation May be Associated with the Later Occurrence of Protein-Losing Enteropathy in Fontan Patients : Association of Early Glenn and Failing Fontan. *Paediatric cardiology*. 2017;38(6):1155-61.
9. Schumacher KR, Singh TP, Kuebler J, Aprile K, O'Brien M, Blume ED. Risk factors and outcome of Fontan-associated plastic bronchitis: a case-control study. *Journal of the American Heart Association*. 2014;3(2):e000865.
10. John AS, Johnson JA, Khan M, Driscoll DJ, Warnes CA, Cetta F. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation. *Journal of the American College of Cardiology*. 2014;64(1):54-62.
11. Pundi KN, Johnson JN, Dearani JA, Pundi KN, Li Z, Hinck CA, et al. 40-Year Follow-Up After the Fontan Operation: Long-Term Outcomes of 1,052 Patients. *J Am Coll Cardiol*. 2015;66(15):1700-10.
12. d'Udekem Y, Iyengar AJ, Galati JC, Forsdick V, Weintraub RG, Wheaton GR, et al. Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand. *Circulation*. 2014;130(11 Suppl 1):S32-8.
13. Shiraishi S, Yagihara T, Kagisaki K, Hagino I, Ohuchi H, Kobayashi J, et al. Impact of age at Fontan completion on postoperative hemodynamics and long-term aerobic exercise capacity in patients with dominant left ventricle. *The Annals of thoracic surgery*. 2009;87(2):555-60; discussion 60-1.
14. ElMallah MK, Prabhakaran S, Chesrown SE. Plastic bronchitis: resolution after heart transplantation. *Paediatric pulmonology*. 2011;46(8):824-5.
15. Brooks K, Caruthers RL, Schumacher KR, Stringer KA. Pharmacotherapy challenges of Fontan-associated plastic bronchitis: a rare paediatric disease. *Pharmacotherapy*. 2013;33(9):922-34.

16. Okada S, Muneuchi J, Nagatomo Y, Nonaka K, Iida C, Shirouzu H, et al. Successful Treatment of Protein-Losing Enteropathy and Plastic Bronchitis by Biphase Cuirass Ventilation in a Patient with Failing Fontan Circulation. *International heart journal*. 2018;59(4):873-6.
17. Shah SS, Drinkwater DC, Christian KG. Plastic bronchitis: is thoracic duct ligation a real surgical option? *The Annals of thoracic surgery*. 2006;81(6):2281-3.
18. Zahorec M, Kovacikova L, Martanovic P, Skrak P, Kunovsky P. The use of high-frequency jet ventilation for removal of obstructing casts in patients with plastic bronchitis. *Paediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Paediatric Intensive and Critical Care Societies*. 2009;10(3):e34-6.
19. Preciado D, Verghese S, Choi S. Aggressive bronchoscopic management of plastic bronchitis. *International journal of paediatric otorhinolaryngology*. 2010;74(7):820-2.
20. Heath L, Ling S, Racz J, Mane G, Schmidt L, Myers JL, et al. Prospective, longitudinal study of plastic bronchitis cast pathology and responsiveness to tissue plasminogen activator. *Paediatric cardiology*. 2011;32(8):1182-9.
21. Avitabile CM, Goldberg DJ, Dodds K, Dori Y, Ravishankar C, Rychik J. A multifaceted approach to the management of plastic bronchitis after cavopulmonary palliation. *The Annals of thoracic surgery*. 2014;98(2):634-40.
22. Do TB, Chu JM, Berdjis F, Anas NG. Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature. *Paediatric cardiology*. 2009;30(3):352-5.
23. Lubcke NL, Nussbaum VM, Schroth M. Use of aerosolized tissue plasminogen activator in the treatment of plastic bronchitis. *The Annals of pharmacotherapy*. 2013;47(3):e13.
24. Colaneri M, Quarti A, Pozzi M, Gasparini S, Carloni I, de Benedictis FM. Management of plastic bronchitis with nebulized tissue plasminogen activator: another brick in the wall. *Italian journal of pediatrics*. 2014;40(1):18.
25. Wakeham MK, Van Bergen AH, Torero LE, Akhter J. Long-term treatment of plastic bronchitis with aerosolized tissue plasminogen activator in a Fontan patient. *Paediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Paediatric Intensive and Critical Care Societies*. 2005;6(1):76-8.
26. Dori Y, Keller MS, Rome JJ, Gillespie MJ, Glatz AC, Dodds K, et al. Percutaneous Lymphatic Embolization of Abnormal Pulmonary Lymphatic Flow as Treatment of Plastic Bronchitis in Patients With Congenital Heart Disease. *Circulation*. 2016;133(12):1160-70.
27. Onoue Y, Adachi Y, Ichida F, Miyawaki T. Effective use of corticosteroid in a child with life-threatening plastic bronchitis after Fontan operation. *Pediatrics international : official journal of the Japan Paediatric Society*. 2003;45(1):107-9.
28. Schultz KD, Oermann CM. Treatment of cast bronchitis with low-dose oral azithromycin. *Paediatric pulmonology*. 2003;35(2):139-43.
29. Ugaki S, Lord DJ, Sherwood MC, Winlaw DS. Lymphangiography is a diagnostic and therapeutic intervention for patients with plastic bronchitis after the Fontan operation. *The Journal of thoracic and cardiovascular surgery*. 2016;152(2):e47-9.
30. McMahon CJ, Nihill MR, Reber A. The bronchial cast syndrome after the fontan procedure: further evidence of its etiology. *Cardiology in the young*. 2001;11(3):345-51.
31. Reinhardt Z, Uzun O, Bhole V, Ofoe V, Wilson D, Onuzo O, et al. Sildenafil in the management of the failing Fontan circulation. *Cardiology in the young*. 2010;20(5):522-5.
32. Haseyama K, Satomi G, Yasukochi S, Matsui H, Harada Y, Uchita S. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. *The Journal of thoracic and cardiovascular surgery*. 2006;132(5):1232-3.

33. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2005;24(8):1174-6.
34. Barber BJ, Burch GH, Tripple D, Balaji S. Resolution of plastic bronchitis with atrial pacing in a patient with fontan physiology. *Paediatric cardiology*. 2004;25(1):73-6.
35. Quasney MW, Orman K, Thompson J, Ring JC, Salim M, Schoumacher RA, et al. Plastic bronchitis occurring late after the Fontan procedure: treatment with aerosolized urokinase. *Critical care medicine*. 2000;28(6):2107-11.
36. Wilson J, Russell J, Williams W, Benson L. Fenestration of the Fontan circuit as treatment for plastic bronchitis. *Paediatric cardiology*. 2005;26(5):717-9.
37. Parikh K, Witte MH, Samson R, Teodori M, Carpenter JB, Lowe MC, et al. Successful treatment of plastic bronchitis with low fat diet and subsequent thoracic duct ligation in child with fontan physiology. *Lymphology*. 2012;45(2):47-52.
38. Tanase D, Ewert P, Eicken A. Plastic bronchitis: symptomatic improvement after pulmonary arterial stenting in four patients with Fontan circulation. *Cardiology in the young*. 2015;25(1):151-3.
39. Hallbergson A, Mascio CE, Rome JJ. Transcatheter Fontan takedown. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2015;86(5):849-54.
40. Kobayashi D, Turner DR, Forbes TJ. Transhepatic approach to create stent fenestration in the extracardiac Fontan conduit in a child with dextrocardia and interrupted inferior vena cava with azygos continuation. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2013;81(5):843-8.
41. DePopas EM, Veress LA, Ahmed F, Rausch CM, Annam A, Gupta R. Percutaneous thoracic duct intervention to treat plastic bronchitis related to Fontan palliation. *Paediatric pulmonology*. 2017;52(11):E97-e101.
42. Do P, Randhawa I, Chin T, Parsapour K, Nussbaum E. Successful management of plastic bronchitis in a child post Fontan: case report and literature review. *Lung*. 2012;190(4):463-8.
43. Charlagorla P, Breinholt JP. Creating a Fontan fenestration in a child with dextrocardia and interrupted inferior vena cava. *Annals of paediatric cardiology*. 2016;9(2):179-82.
44. Chaudhari M, Stumper O. Plastic bronchitis after Fontan operation: treatment with stent fenestration of the Fontan circuit. *Heart (British Cardiac Society)*. 2004;90(7):801.
45. Wesnerowicz A, Nawrocki P, Wagner K, Malec E, Januszewska K. Management of plastic bronchitis after Fontan operation with resolution of symptoms. *Kardiologia polska*. 2016;74(5):490.
46. Kunder R, Kunder C, Sun HY, Berry G, Messner A, Frankovich J, et al. Paediatric plastic bronchitis: case report and retrospective comparative analysis of epidemiology and pathology. *Case reports in pulmonology*. 2013;2013:649365.
47. Gossett JG, Almond CS, Kirk R, Zangwill S, Richmond ME, Kantor PF, et al. Outcomes of cardiac transplantation in single-ventricle patients with plastic bronchitis: a multicenter study. *Journal of the American College of Cardiology*. 2013;61(9):985-6.
48. Griffiths ER, Kaza AK, Wyler von Ballmoos MC, Loyola H, Valente AM, Blume ED, et al. Evaluating failing Fontans for heart transplantation: predictors of death. *The Annals of thoracic surgery*. 2009;88(2):558-63; discussion 63-4.
49. Parent JJ, Darragh RK. Severe airway obstruction from a bronchial cast after cardiac transplantation. *Cardiology in the young*. 2014;24(4):739-40.
50. Parent JJ, Darragh RK, Gossett JG, Ryan TD, Villa CR, Lorts A, et al. Strategies to Prevent Cast Formation in Patients with Plastic Bronchitis Undergoing Heart Transplantation. *Paediatric cardiology*. 2017;38(5):1077-9.

Chapter 8

51. Schumacher KR, Yu S, Butts R, Castleberry C, Chen S, Edens E, et al. Fontan-associated protein-losing enteropathy and postheart transplant outcomes: A multicenter study. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2019;38(1):17-25.

Supplementary materials

Table S1. Overview of included records

Study	N cases	Age at diagnosis of PB median (min-max) months	Interval Fontan operation until PB median (min-max) months	Follow-up since diagnosis of PB median (min-max) months	Outcome		Symptomatic cast relief		Anti-inflammatory treatment		Therapy				
					Died (N cases)	Y/N	N cases	Y/N	N cases	Y/N	Opt	Rhyt	Lymph	Dec	HTx
Okada et al. 2018 ¹⁶	1	192	171	0.5		Yes	1	Yes	1	No					
DePopas et al. 2017 ⁴¹	3	60 (72-108)	24 (24-48)	45 (42.5-73)		Yes	3	No	3	Yes	3	1	1	2	1
Parent et al. 2017 ⁵⁰	3	-	-	54 (48-90)		Yes	3	Yes	3	Yes	3				
Perez Ruiz et al. 2017 ⁵²	1	17	-	1	1	Yes	1	No	No	No				1	3
Unselid et al. 2017 ⁸	4	50.4 (39.6-61.2)	15.6 (4.8-27.6)	58.2 (12-88.8)	2	ND	ND	ND	ND	ND					
Charlagorla et al. 2016 ⁴³	1	60	30	24		Yes	1	Yes	1	Yes	1				1
Dori et al. 2016 ²⁶	16	65.6 (20.8-136.6)	20.6 (0-51.6)	32.2 (13.7-100.6)	1	Yes	15	Yes	13	Yes	16	16	1	15	3
Guevara et al. 2016 ⁵³	1	-	-	-		Yes	1	No	No	Yes	1				
Ugaki et al. 2016 ²⁹	1	51	3	8	1	Yes	1	No	No	Yes	1	1	1	1	1
Wesnerowicz et al. 2016 ⁴⁵	2	79.8 (21-138.5)	52.8 (9-96.5)	26.8 (24-29.5)		Yes	2	Yes	1	Yes	2	2			1
Chung et al. 2015 ⁵⁴	1	60	51	65		Yes	1	No	No	Yes	1			1	
Hallbergson et al. 2015 ³⁹	2	84 (38.4-129.6)	2.9 (0.8-5)	14 (4-24)	1	No	No	No	No	Yes	2				2

Table S1. Overview of included records (continued)

Study	N cases	Age at diagnosis of PB median (min-max) months	Interval Fontan operation until PB median (min-max) months	Follow-up since diagnosis of PB median (min-max) months	Outcome		Symptomatic cast relief		Anti-inflammatory treatment		Therapy							
					Died (N cases)	1	Y/N	N cases	Y/N	N cases	Y/N	N cases	Tot cases	Opt	Rhyt	Lymp	Dec HTx	
Jasinovic et al. 2015 ⁵⁵	2	66.5 (56-77)	-	20.5 (3-38)		1	Yes	2	No	No								
Singhi et al. 2015 ⁵⁶	1	62	2	9		No	No		No	No	Yes	1	1					
Tanase et al. 2015 ³⁸	4	29 (21.5-45)	10 (0.5-24)	10.8 (5-25)		Yes	4		No		Yes	4	4					
Avitable et al. 2014 ²¹	14	-	18.0 (0.3-184.8) (1 Missing)	32.4 (3-54)		Yes	14		Yes	14	Yes	14	14		1	7	3	
Colaneri et al. 2014 ²⁴	1	156	84	12		Yes	1		Yes	1	Yes	1	1					
Dori et al. 2014 ⁵⁷	1	68	32	11.7		Yes	1		Yes	1	Yes	1	1		1			
Eason et al. 2014 ⁵⁸	1	60	24	12		Yes	1		Yes	1	Yes	1	1		1			
Lis et al.; 2014 ⁵⁹	1	18	-	1.1		Yes	1		Yes	1	Yes	1	1		1			
Parent et al. 2014 ⁴⁹	1	-	-	-		Yes	1		No		Yes	1	1		1		1	
Brooks et al. 2013 ¹⁵	2	54.0 (41-66.9)	36.5 (24-48.9)	132 (1 Missing)		Yes	2		Yes	1	No							
Ezmigna et al. 2013 ⁶⁰	1	72	24	15.4		Yes	1		Yes	1	Yes	1	1		1			
Grutter et al. 2013 ⁶¹	1	144	60	18		Yes	1		Yes	1	Yes	1	1		1			
Kobayashi et al. 2013 ⁴⁰	1	42	6	8		Yes	1		Yes	1	Yes	1	1		1			
Kunder et al. 2013 ⁴⁶	4	33 (24-36)	1 (3 Missing)	7.5 (3-144)		Yes	4		Yes	4	Yes	3	2				2	
Lubcke et al. 2013 ²³	1	144	120	9		Yes	1		Yes	1	Yes	1	1		1			
Singhal et al. 2013 ⁶²	2	101.5 (83-120)	65.5 (35-96)	7.5 (2-13)		Yes	2		Yes	1	Yes	2	2		1	1		
Do et al. 2012 ⁴²	1	132	72	9		Yes	1		Yes	1	Yes	1	1		1		1	

Table S1. Overview of included records (continued)

Study	N cases	Age at diagnosis of PB median (min-max) months	Interval Fontan operation until PB median (min-max) months	Follow-up since diagnosis of PB median (min-max) months	Outcome		Symptomatic cast relief		Anti-inflammatory treatment		Hemodynamics (CO/CVP/Lymph)	
					Died (N cases)	Y/N	N cases	Y/N	N cases	Y/N	Tot cases	Dec HTx
Elahi et al. 2012 ⁶³	1	48	6	0,33		Yes	1	No		No		
Grutter et al. 2012 ⁶⁴	4	43 (25-54)	4 (0-10)	7 (0-10)	2	Yes	4	Yes	4	Yes	4	
Kovesi et al. 2012 ⁶⁵	1	13	-	67,4		Yes	1	Yes	1	Yes	1	
Larue et al. 2012 ⁵	2	121 (38-204)	79 (2-156)	36 (30-42)		Yes	2	Yes	2	Yes	2	1
Nawa et al. 2012 ⁶⁶	1	96	60	1		Yes	1	No		Yes	1	
Parikh et al. 2012 ³⁷	1	132	110	72		Yes	1	Yes	1	Yes	1	1
Wirbelauer et al. 2012 ⁶⁷	1	60	36	24		Yes	1	No		Yes	1	1
Elmallah et al. 2011 ¹⁴	1	72	-	42		Yes	1	Yes	1	Yes	1	1
Laubisch et al. 2011 ⁶⁸	1	48	24	32		Yes	1	Yes	1	Yes	1	1
Silva et al. 2011 ⁶⁹	1	60	-	2,4	1	Yes	1	Yes	1	Yes	1	1
Guimaraes et al. 2010 ⁷⁰	1	54	14	3		Yes	1	No		Yes	1	
Preciado et al. 2010 ¹⁹	3	36 (8-36)	6 (2 Missing)	2 (0-4,7)	1	Yes	3	Yes	2	No		
Reinhardt et al. 2010 ³¹	4	117,6 (81,6-148,8) (1 missing)	78 (42-96) (1 missing)	21,4 (12-30,8) (2 missing)		No		No		Yes	4	3
Do et al. 2009 ²²	1	68	2	1		Yes	1	No		Yes	1	1
Zahorec et al. 2009 ¹⁸	2	127,4 (74-180,8)	1,4 (0,8-2)	32 (4-60)	1	Yes	2	Yes	1	No		
Cajalaba et al. 2008 ⁷¹	1	192	144	0,16	1	Yes	1	No		No		

Table S1. Overview of included records (continued)

Study	N cases	Age at diagnosis of PB median (min-max) months	Interval Fontan operation until PB (min-max) months	Follow-up since diagnosis of PB median (min-max) months	Outcome		Symptomatic cast relief		Anti-inflammatory treatment		Therapy								
					Died (N cases)	Y/N	N cases	Y/N	N cases	Y/N	N cases	Tot cases	Rhyt	Lymph	Dec	HTx			
Verghese et al. 2008 ⁷²	1	32	14				Yes	1	No										
Zaccagni et al. 2008 ⁷³	1	180	108	17			Yes	1	No			Yes	1	1					
Nayar et al. 2007 ⁷⁴	1	102	15	2	1		Yes	1	Yes	1		Yes	1					1	
Haseyama et al. 2006 ³²	1	38	2	9		No	No		Yes	1		Yes	1	1					
Apostolopoulou et al. 2005 ³³	1	92	8	91,6			Yes	1	Yes	1		Yes	1	1				1	
Shah et al. 2006 ¹⁷	2	48 (1 Missing)	36 (1 Missing)	14.5 (5-24)			Yes	1	Yes	1		Yes	1	2				2	
Peleg et al. 2005 ⁷⁵	1	75	3	4	1		Yes	1	Yes	1		No							
Tzifa et al. 2005 ⁷⁶	1	41	5	8,5			Yes	1	Yes	1		Yes	1	1					
Wakeham et al. 2005 ²⁵	1	50	35	31			Yes	1	Yes	1		Yes	1	1	1	1			
Wilson et al. 2005 ³⁶	1	61	1	15			Yes	1	Yes	1		Yes	1	1				1	
Yalcin et al. 2005 ⁷⁷	1	90	60	17			Yes	1	No			Yes	1	1					
Barber et al. 2004 ³⁴	1	54	6	15			Yes	1	No			Yes	1	1					
Chaudhari et al.; 2004 ⁴⁴	1	42	1	36			Yes	1	Yes	1		Yes	1	1				1	
Dicindio et al. 2004 ⁷⁸	1	28	10	0,46	2		Yes	1	Yes	1		No							
Ishman et al. 2003 ⁷⁹	1	60	7	12			Yes	1	No			No							
Onoue et al. 2003 ²⁷	1	96	60	36,7			Yes	1	Yes	1		No							

Table S1. Overview of included records (continued)

Study	N cases	Age at diagnosis of PB (min-max) months	Interval Fontan operation until PB (min-max) months	Follow-up since diagnosis of PB (min-max) months	Outcome		Symptomatic cast relief		Anti-inflammatory treatment		Hemodynamics (CO/CVP/Lymph)	
					Died (N cases)	Y/N	N cases	Y/N	N cases	Y/N	Tot cases	Dec HTx
Brogan et al. 2002 ¹	1	65	5	20		Yes	1	Yes	1	Yes	1	1
Costello et al. 2002 ⁸⁰	1	53	27	5.2		Yes	1	Yes	1	No		
Stiller et al. 2002 ⁸¹	2	57 (42-72)	26.5 (17-36)	18 (12-24)		Yes	2	Yes	2	Yes	2	2
Hug et al. 2001 ⁸²	1	47.4	1.4	0		Yes	1	No		No		
McMahon et al. 2001 ³⁰	1	30	6	7.4		Yes	1	Yes	1	Yes	1	1
Setzer et al. 2001 ⁸³	1	72.2	0.16	0.16	1	Yes	1	No		No		
Quasney et al. 2000 ³⁵	1	60	24	36.5		Yes	1	Yes	1	Yes	1	1
Collorodi et al. 1990 ⁸⁴	1	84	-	-	1	Yes	1	No		No		
Languepin et al. 1999 ⁸⁵	1	24	9	64		Yes	1	Yes	1	Yes	1	1
Seear et al. 1997 ⁸⁶	3	96 (60-144)	12 (12-12) 1Missing	0.69 (0.46-1.2)		Yes, 2ND	1	Yes, 2ND	1	No, 2ND		
Bowen et al. 1985 ⁸⁷	1	101	5	37	1	No		Yes	1	No		
Own case	1	70	19	77		Yes	1	Yes	1	Yes	1	1

CO= Cardiac output; CVP= Central Venous Pressure; Dec= Therapy for decompression of Fontan circulation; HTx= Heart transplantation; Lymph= Therapy for inhibition of lymph leakage/production; N cases = Number of cases; ND = Not defined; Opt= Therapy for optimizing Fontan circulation; Rhyt= Anti-arrhythmic therapy; Y/N= Yes/No.
 * Not all variables that were investigated in this systematic review are included in this table.

Extra references (only in supplementary table):

52. Perez Ruiz E, Lopez Castillo MC, Caro Aguilera P, Perez Frias J. *Management and Treatment of Paediatric Plastic Bronchitis*. Arch Bronconeumol 2017;53:467-68.
53. Guevara CJ, Rialon KL, Ramaswamy RS, Kim SK, Darcy MD. *US-Guided, Direct Puncture Retrograde Thoracic Duct Access, Lymphangiography, and Embolization: Feasibility and Efficacy*. J Vasc Interv Radiol 2016;27:1890-96.
54. Chung A, Gill AE, Rahman FN, Hawkins CM. *Retrograde Thoracic Duct Embolization in a Paediatric Patient with Total Cavopulmonary Connection and Plastic Bronchitis*. J Vasc Interv Radiol 2015;26:1743-6.
55. Jasinovic T, Kozak FK, Moxham JP, Chilvers M, Wensley D, Seear M et al. *Casting a look at paediatric plastic bronchitis*. Int J Pediatr Otorhinolaryngol 2015;79:1658-61.
56. Singhi AK, Vinoth B, Kuruvilla S, Sivakumar K. *Plastic bronchitis*. Ann Pediatr Cardiol 2015;8:246-8.
57. Dori Y, Keller MS, Rychik J, Itkin M. *Successful treatment of plastic bronchitis by selective lymphatic embolization in a Fontan patient*. Pediatrics 2014;134:e590-5.
58. Eason DE, Cox K, Moskowitz WB. *Aerosolised heparin in the treatment of Fontan-related plastic bronchitis*. Cardiol Young 2014;24:140-2.
59. Lis G, Cichocka-Jarosz E, Jedynak-Wasowicz U, Glowacka E. *Add-on treatment with nebulized hypertonic saline in a child with plastic bronchitis after the Glenn procedure*. J Bras Pneumol 2014;40:82-5.
60. Ezmigna DR, Morgan WJ, Witte MH, Brown MA. *Lymphoscintigraphy in plastic bronchitis, a paediatric case report*. Pediatr Pulmonol 2013;48:515-8.
61. Grutter G, Di Carlo D. *Plastic bronchitis after extracardiac Fontan operation: further evidence*. Ann Thorac Surg 2013;95:2214-5.
62. Singhal NR, Da Cruz EM, Nicolarsen J, Schwartz LI, Merritt GR, Barrett C et al. *Perioperative management of shock in two fontan patients with plastic bronchitis*. Semin Cardiothorac Vasc Anesth 2013;17:55-60.
63. Elahi M, Poh CL, Ravindranathan H, Grant P. *Barotrauma as aetiological cascade of fatal intrapulmonary plastic bronchitis in a post-Fontan child*. Interact Cardiovasc Thorac Surg 2012;15:805-7.
64. Grutter G, Di Carlo D, Gandolfo F, Adorisio R, Alfieri S, Michielon G et al. *Plastic bronchitis after extracardiac Fontan operation*. Ann Thorac Surg 2012;94:860-4.
65. Kovesi T, Gardin L. *Bronchial cast*. Pediatr Cardiol 2012;33:675-6.
66. Nawa T, Yokozawa M, Takamuro M, Kasuga A. *Plastic bronchitis developing 5 years after Fontan procedure in a girl with Kartagener's syndrome*. Pediatr Cardiol 2012;33:846-9.
67. Wirbelauer J, Bauer J, Hebestreit H, Thomas W. *Plastic bronchitis 3 years after Fontan palliation*. Klin Padiatr 2012;224:38-9.
68. Laubisch JE, Green DM, Mogayzel PJ, Reid Thompson W. *Treatment of plastic bronchitis by orthotopic heart transplantation*. Pediatr Cardiol 2011;32:1193-5.
69. Silva RC, Simons JP, Chi DH, Yellon RF, Alper CM. *Endoscopic treatment of plastic bronchitis*. Arch Otolaryngol Head Neck Surg 2011;137:401-3.
70. Guimaraes VA, Atik E, Castelli JB, Ikari NM, Thomaz AM, Lopes AA. *[Association of plastic bronchitis to protein-losing enteropathy after fontan operation]*. Arq Bras Cardiol 2010;94:e109-12.
71. Cajaiba MM, Borralho P, Reyes-Mugica M. *The potentially lethal nature of bronchial casts: plastic bronchitis*. Int J Surg Pathol 2008;16:230-2.
72. Verghese S, Jackson M, Vaughns J, Preciado D. *Plastic bronchitis in a child with Fontan's physiology presenting for urgent rigid bronchoscopy*. Anesth Analg 2008;107:1446-7.

73. Zaccagni HJ, Kirchner L, Brownlee J, Bloom K. *A case of plastic bronchitis presenting 9 years after Fontan*. *Pediatr Cardiol* 2008;29:157-9.
74. Nayar S, Parmar R, Kulkarni S, Cherian KM. *Treatment of plastic bronchitis*. *Ann Thorac Surg* 2007;83:1884-6.
75. Peleg U, Schwartz S, Sirota G, Hochman I, Cohen D, Picard E. *Persistent plastic bronchitis in a child after cardiac surgery*. *Isr Med Assoc J* 2005;7:122-4.
76. Tzifa A, Robards M, Simpson JM. *Plastic bronchitis; a serious complication of the Fontan operation*. *Int J Cardiol* 2005;101:513-4.
77. Yalcin E, Ozelik U, Celiker A. *Plastic bronchitis occurring late after the Fontan procedure in a child: treatment with stent implantation in the left pulmonary artery*. *J Invasive Cardiol* 2005;17:326-8.
78. DiCindio S, Theroux M, Costarino AT, Jr., Cook S, O'Reilly R. *Plastic bronchitis: a case report*. *Paediatr Anaesth* 2004;14:520-3.
79. Ishman S, Book DT, Conley SF, Kerschner JE. *Plastic bronchitis: an unusual bronchoscopic challenge associated with congenital heart disease repair*. *Int J Pediatr Otorhinolaryngol* 2003;67:543-8.
80. Costello JM, Steinhorn D, McColley S, Gerber ME, Kumar SP. *Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature*. *Pediatrics* 2002;109:e67.
81. Stiller B, Riedel F, Paul K, van Landeghem FK. *Plastic bronchitis in children with Fontan palliation: analogue to protein losing enteropathy?* *Pediatr Cardiol* 2002;23:90-4.
82. Hug MI, Ersch J, Moenkhoef M, Burger R, Fanconi S, Bauersfeld U. *Chylous bronchial casts after fontan operation*. *Circulation* 2001;103:1031-3.
83. Setzer N, Malvezzi L, McBride W. *"Plastic bronchitis" complicating recovery from congenital heart surgery*. *J Pediatr* 2001;138:605.
84. Colloridi V, Roggini M, Formigari R, Ventriglia F, Giglioni E. *Plastic bronchitis as a rare complication of Fontan's operation*. *Pediatr Cardiol* 1990;11:228.
85. Languepin J, Scheinmann P, Mahut B, Le Bourgeois M, Jaubert F, Brunelle F *et al*. *Bronchial casts in children with cardiopathies: the role of pulmonary lymphatic abnormalities*. *Pediatr Pulmonol* 1999;28:329-36.
86. Seear M, Hui H, Magee F, Bohn D, Cutz E. *Bronchial casts in children: a proposed classification based on nine cases and a review of the literature*. *Am J Respir Crit Care Med* 1997;155:364-70.
87. Bowen A, Oudjhane K, Odagiri K, Liston SL, Cumming WA, Oh KS. *Plastic bronchitis: large, branching, mucoid bronchial casts in children*. *AJR Am J Roentgenol* 1985;144:371-5.